Boston Scientific To Participate In Goldman Sachs CEOs Unscripted Healthcare Conference

MARLBOROUGH, Mass., Dec. 18, 2014 /PRNewswire/ -- Boston Scientific Corporation BSX is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January 6, 2015 in Boston.

Mike Mahoney, president and chief executive officer, and Dan Brennan, executive vice president and chief financial officer will participate in a 40-minute question and answer session regarding the company beginning at approximately 9:30 a.m. ET.

A live webcast of the presentation and question and answer session will be available via the Boston Scientific website. Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors. Registration at least 15 minutes prior to the scheduled start time is encouraged to ensure a timely connection.

The webcast is being hosted by Goldman Sachs. A replay of the webcast will be archived and accessible at http://www.bostonscientific.com/investors beginning approximately one hour following the completion of the question and answer session.  

About Boston Scientific 
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS 
Media: 
Kelly Leadem
508-683-5543 (office)
Media Relations
Boston Scientific Corporation 
kelly.leadem@bsci.com  

Investors: 
Susie Lisa, CFA
508- 683-5565 (office)
Investor Relations
Boston Scientific Corporation 
investor_relations@bsci.com  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-to-participate-in-goldman-sachs-ceos-unscripted-healthcare-conference-300011583.html

SOURCE Boston Scientific Corporation